idea-005 · desirability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the parents of a child waiting for a sleep study, the pediatric sleep physician who reads it, and the ENT who would operate on the strength of it.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-005.md — the number is the claim's position in its ## Claims list, the tag is copied from it and never adjusted here. A [no claim] marker means nothing in the file speaks to the condition at all. See docs/deck-spec.md.
What changed since the 2026-08-24 build — this deck's central statement is now wrong and has been replaced. That build said this candidate "has no verified claims at all". It now has seven [claim 26: verified] through [claim 32: verified], and they are the most consequential evidence in this file. One of them answers this deck's load-bearing question directly, and the answer is adverse. Rebuilt from the file, not patched.
Would have to be true: Children referred for suspected OSA would have to be waiting long enough for an in-lab bed that a home study is worth the trade — and there would have to be enough of them.
Where it stands: The wait is now evidenced, though not in the US: in a Québec quality-improvement study of 82 consecutive pediatric adenotonsillectomy patients, mean referral-to-consultation delay was 9.0±7.0 months and total referral-to-surgery delay was 15.2±8.6 months, substantially exceeding the region's own surgical access targets [claim 32: verified]. That is a real, verified measure of how slow this pathway is — in a single-payer Canadian system, which is not the US market this candidate launches into, and the claim carries jurisdiction: US while describing non-US data. The US wait-list premise stays unbacked [claim 15: unconfirmed], as do referral volume and obtainable share [claim 5: unconfirmed], [claim 7: unconfirmed]. Prevalence is verified and wide: the 2012 AAP technical report reviewing 3,166 titles found pediatric OSAS prevalence ranging from 0% to 5.7% across the literature [claim 29: verified].
What would settle it: US pediatric sleep centre wait-time data, human-attached — AASM accredited-centre surveys or a children's hospital's own queue; a commercial or Medicaid claims extract for pediatric PSG volume, since Medicare will not show it.
If it's false: There is no problem to move out of the lab, and the candidate's stated obtainable segment is measuring a queue that may not exist at the size assumed.
Would have to be true: A parent would have to fit a cannula, a thermistor, two effort belts and an oximeter probe on their own child at bedtime — and the child would have to sleep in it, first try.
Where it stands: Both halves remain unbacked for this device [claim 16: unconfirmed], [claim 17: unconfirmed] — and the best available evidence says this is not where the product fails. In an Australian study of 47 children aged 5-16 undergoing home Type-2 polysomnography, acceptable recordings were obtained for every home study attempted [claim 31: verified]. Read that carefully before taking comfort from it: a Type-2 montage includes EEG, so it is a heavier setup than the one this candidate proposes, and it succeeded anyway. Home application by families is, on this evidence, a solved problem. The candidate's difficulty lies elsewhere.
What would settle it: First-night technical failure rates from the pediatric HSAT literature and from the registered trials the file points at [claim 4: unconfirmed] — those trials measure exactly this and their protocols are public.
If it's false: Repeat studies erase the cost advantage over the in-lab test, and the parent's experience of failure is worse than the wait would have been.
Would have to be true: A pediatric sleep physician would have to read an unattended study as sufficient, and an ENT would have to operate on the strength of it.
Where it stands: This is now answered at the level of professional-society guidance, and it is answered no. The AASM's 2017 Position Paper states that use of a home sleep apnea test is not recommended for the diagnosis of obstructive sleep apnea in children — and the stated reason is an inability to identify literature on HSAT devices that monitor CO2 or detect arousals, measurements the task force viewed as critical in pediatric populations [claim 28: verified]. That objection is not incidental to this candidate; arousal detection requires EEG, and an EEG-free montage is precisely what this product proposes. The individual clinician questions remain unbacked [claim 14: unconfirmed], [claim 18: unconfirmed], but they now sit downstream of a published position rather than in open space.
What would settle it: Interviews with pediatric sleep physicians and pediatric otolaryngologists on how much the 2017 position actually binds their practice, and what evidence would move it — the position paper is nine years old and the concordance literature has grown since [claim 30: verified]. AAO-HNS practice guidance on home testing in children, read by a human.
If it's false: The result becomes a triage tool that still ends in a lab study for anyone being considered for surgery — a smaller product than the one described, and one whose reimbursement argument no longer works.
Would have to be true: The burden of a home study — equipment, a disrupted night, a possible repeat — would have to stay under the burden of the wait plus the lab night it replaces, and the risk of being wrong would have to be acceptable.
Where it stands: The wait side of the trade is now quantified, if non-US [claim 32: verified]. The accuracy side has verified numbers for the first time, and they are better than the last build could report: a 6.6% false-positive and 3% false-negative rate for OSA diagnosis in the Australian home cohort [claim 31: verified] — again, on a Type-2 montage that includes EEG. The candidate's own dominant risk remains false negatives on an EEG-free montage [claim 11: unconfirmed], and the verified prevalence range is wide enough that the pre-test probability varies a great deal by population [claim 29: verified]. What a family would actually be charged is still unknown [claim 8: unconfirmed].
What would settle it: A payer policy read for what a family would actually be charged; and the false-negative rate for the EEG-free montage specifically, which [claim 31: verified] does not supply.
If it's false: The product is asking families to accept a diagnostic with a known blind spot in exchange for convenience — a trade a paediatrician will frame for them, not a marketer.
Would have to be true: There would have to be a concurrent-PSG validation in children, in this age range, showing agreement good enough that a specialist changes practice.
Where it stands: Partly, and the qualification matters more than the result. A 2026 systematic review of pediatric HSAT-versus-PSG concordance found that only 3 of 9 included studies used simultaneous HSAT and PSG testing — and in one of the largest of those, mean AHI was 2.5±3 by HSAT versus 2.7±2.9 by PSG, p>0.05 [claim 30: verified]. So concurrent evidence exists, is favourable where it exists, and is thin: three studies. That is simultaneously the best argument this candidate has and a precise description of the gap its own multi-site study [claim 12: unconfirmed] would fill. Against it stands the AASM position [claim 28: verified] and the AAP's finding that most diagnostic screening tests in this condition had low sensitivity and specificity [claim 29: verified].
What would settle it: Read the three simultaneous studies inside [claim 30: verified] for their montages and thresholds — the cheapest act on this deck, and the one that determines whether the candidate's study is a replication or a first. Then the registered trials' protocols [claim 4: unconfirmed].
If it's false: There is nothing to persuade with, and the belief question stays where it is today — with specialists who require a lab study [claim 14: unconfirmed].
Would have to be true: Ten conversations with pediatric sleep physicians and ENTs, plus the public trial records, would have to tell you whether this is wanted before the multi-million dollar study is commissioned.
Where it stands: Still no primary research, and the file records an honest failure to substitute for it: parent preference was written up as "unanswerable directly", and a US-specific PSG no-show, cancellation or dropout rate was searched for and not found [claim 33: unconfirmed]. The nearest revealed-behaviour evidence is the referral-delay study [claim 32: verified], which quantifies the burden of the in-lab pathway but says nothing about uptake of a home alternative. (Note: [claim 33: unconfirmed] points at "claim 38" for that twin; the file has 33 claims and the study it describes is [claim 32: verified].)
What would settle it: The clinician interviews, framed around the device that already exists rather than the one proposed — and framed around [claim 28: verified], which is the document those clinicians will cite back.
If it's false: The idea is a regulatory strategy in search of a clinical demand, and the demand was assumed from a queue nobody measured [claim 15: unconfirmed].
Every condition above with nothing verified behind it.
The file's premise was refuted and that remains the most important structural fact here: a cleared home airflow/effort recorder already states verbatim that "both pediatric and adult patients may be tested" [claim 3: refuted], from a roster of 38 MNR clearances. The user's access to home testing was never blocked by clearance. What the seven new verified claims add is a candidate answer to "then what is stopping them": a professional society that does not recommend it, for a reason that names the channel this device omits [claim 28: verified].
If only one thing from this chair could be checked: whether pediatric sleep physicians and ENTs will act on an unattended study in an otherwise-healthy child [claim 14: unconfirmed], [claim 18: unconfirmed].
It stays load-bearing, and its character has changed from open question to contested one. If clearance were the barrier, the candidate's plan would be the answer; but a device permitting pediatric home testing is already cleared [claim 3: refuted] and the practice has not moved. The last build listed coverage [claim 8: unconfirmed] and clinical acceptance [claim 14: unconfirmed] as the two candidate explanations. There is now verified evidence for the second: the AASM does not recommend HSAT for pediatric OSA diagnosis, citing the absence of arousal and CO2 monitoring [claim 28: verified].
That does not settle it — a 2017 position is not a permanent one, the concordance literature has grown since [claim 30: verified], and no claim in this file establishes how strongly that position binds individual practice. But it changes what the multi-site study [claim 12: unconfirmed] would have to accomplish: not merely demonstrate agreement, but demonstrate it well enough to move a stated society position whose objection is aimed at this device's architecture.
Naming it is not a recommendation, a gate, or a kill.